Immix Biopharma: Convincing CAR-T Study Data and $2 Billion Revenue Potential Bring Focus to Stock

The Business Model and Breakthrough in Cell Therapy Immix Biopharma (IMMX) is a clinical biopharmaceutical company specializing in the development of novel cell therapies for rare diseases and autoimmune disorders. Through its subsidiary Nexcella, the company is advancing its promising flagship product, NXC-201. The primary focus is on combating AL amyloidosis, a devastating and often fatal systemic disease. The business model is based on developing highly innovative CAR-T cell therapies (Chimeric Antigen Receptor T-Cell) that specifically...